Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Filana Therapeutics Inc
FLNA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.4809
0.0109
2.32%
In chiusura: Nov 17, 4:00 PM EST
$0.4800
-0.0009
-0.19%
Post-mercato: 4:00 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Filana Therapeutics Financials
Filana Therapeutics (FLNA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Filana Therapeutics Sees H2 2026 Net Cash Used In Operations Of $11M-$15M; Year-End Cash $38M-$42M
Benzinga Newsdesk
PRO
Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September
Benzinga Newsdesk
PRO
Filana Therapeutics Q3 GAAP EPS $(0.22) vs $(0.22) YoY
Benzinga Newsdesk
PRO
Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of $(0.92) per share
Benzinga Newsdesk
PRO
Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
Benzinga Newsdesk